Anne-Laure Vallier

TL;DR: 6-month trastuzumab treatment is shown to be non-inferior to 12-month treatment in patients with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events, which support consideration of reduced duration trastzumab for women at similar risk of recurrence as to those included in the trial.

TL;DR: Addition of four cycles of bevacizumab to D-FEC in HER2-negative early breast cancer significantly improved pathological complete response, however, whether the improvement in pathologicalcomplete response will lead to improved disease-free and overall survival outcomes is unknown.

TL;DR: This randomised, open-label, 2×2 factorial phase 3 trial (Neo-tAnGo) enrolled women with newly diagnosed breast cancer at 57 centres in the UK to assess safety and efficacy of the addition of gemcitabine to accelerated paclitaxel with epirubicin and cyclophosphamide, and also the effect of sequencing the blocks of epirUBicinand cycloph phosphamide.

TL;DR: Strong evidence is found that SNPs within genes in taxane pharmacokinetic and pharmacodynamic pathways contribute to TRSN risk, however, a large proportion of the inter-individual variability in TRSn remains unexplained.

TL;DR: A data-driven analysis of computational pathology reveals lymphocyte density as an independent predictor of pCR, a histological indicator of chemotherapy response, in women with breast cancer who received neoadjuvant chemotherapy.